Boston Harbor Angels

Boston Harbor Angels is an angel investment group based in Boston, Massachusetts, established in 2004. Composed of experienced business leaders, the group focuses on investing in high-growth, early-stage companies across various sectors, including life sciences, information technology, consumer products, and clean technologies. The organization typically invests in companies seeking between $250,000 and $1.5 million, emphasizing those nearing commercialization with a clear competitive advantage. Boston Harbor Angels aims to partner with entrepreneurs who are open to guidance while demonstrating the ambition and capability to drive their businesses towards success. The group collaborates in the due diligence process, with each member making individual investment decisions. They receive numerous business proposals each month, from which they carefully select a few for presentations, ultimately inviting the most promising companies to present to the entire group for potential investment discussions.

Antonette Ho

Managing Director

Ziad Moukheiber

President and CEO

Past deals in South Carolina

Zylö Therapeutics

Series B in 2022
Zylo Therapeutics, Inc. is a life sciences company based in Greenville, South Carolina, specializing in a sustained-release drug delivery system. Founded in 2017, the company has developed a delivery mechanism that employs patented hydrogel-derived nanoparticles, known as Nanopods™, to facilitate the topical administration of difficult-to-deliver therapeutic agents, including nitric oxide. This innovative system enhances drug delivery capabilities and is designed to improve the treatment of various conditions such as lupus, hair loss, joint pain, and burns. By utilizing engineered amorphous silica particles, Zylo Therapeutics aims to provide a controlled and sustained release of medications, thereby enhancing product performance and patient outcomes.

Zylö Therapeutics

Series A in 2019
Zylo Therapeutics, Inc. is a life sciences company based in Greenville, South Carolina, specializing in a sustained-release drug delivery system. Founded in 2017, the company has developed a delivery mechanism that employs patented hydrogel-derived nanoparticles, known as Nanopods™, to facilitate the topical administration of difficult-to-deliver therapeutic agents, including nitric oxide. This innovative system enhances drug delivery capabilities and is designed to improve the treatment of various conditions such as lupus, hair loss, joint pain, and burns. By utilizing engineered amorphous silica particles, Zylo Therapeutics aims to provide a controlled and sustained release of medications, thereby enhancing product performance and patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.